---

Richard Heyman

Founder, Aragon and Seragon

A nominator comments: “Using selective nuclear hormone receptor modulators Dr. Heyman pioneered a very lean R&D strategy, which yielded the sale of Aragon to J&J for over $1billion in 2013 and Seragon to Roche for $1.7 billion in 2014...The class of drugs developed by Dr. Heyman was developed by rational drug design and to my knowledge are the first successful efforts to modulate these receptors in specific ways.”

---

Part of the Power List 2015

Who are the most influential medicine makers?

That’s the question we posed to ourselves – and then to you – over two months ago, ahead of open nominations and a painstaking judging process. Here, without further ado, we celebrate the answer.

Go to The Power List 2015